Autolus Therapeutics plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| AUTL | ALLO | CABA | 2126.HK | FATE | PGEN | |
|---|---|---|---|---|---|---|
| Market cap | 367.30M | 411.13M | 240.75M | 1.11B | 250.42M | 1.81B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.2 | -1.9 | -1.2 | -3.0 | -2.2 | -23.0 |
| Price/book | 4.9 | 0.9 | 1.1 | 2.0 | 1.6 | 85.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +2.17% | +0.90% | −45.59% | −29.57% | +87.16% | +31.58% |
| Today | −2.47% | +6.25% | 0.00% | +7.91% | +2.45% | −3.71% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All AUTL news ›Autolus Therapeutics (AUTL) Projected to Release Earnings on Tuesday
Posted by Kim Johansen on Nov 3rd, 2026 View Our Latest Stock Analysis on Autolus Therapeutics Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The…
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction
Initiative focused on driving gross profit margin and path to profitability for the ALL business Company will reduce headcount by approximately 13% while doubling manufacturing of products for commercial and clinical trial patients in 2026…
Autolus Therapeutics: Cheap On Sales, Still Far From Breakeven
Autolus Therapeutics' Q2 2026 saw a 74% sales jump to $45.7M and a gross margin expansion to 55%. I rate AUTL stock as Hold. Click to read my full analysis. - Autolus Therapeutics is rated 'Hold' due to uncertainty around sales…
Autolus Therapeutics: Key Questions For The Near Term
Autolus Therapeutics looks undervalued as revenue grows and autoimmune catalysts near. Read here for a detailed analysis of AUTL stock. - Autolus Therapeutics remains a Buy, supported by robust product revenue growth and advancing…
autolus therapeutics - AUTL
Check out the latest Autolus Therapeutics (AUTL) stock quote and chart. View real-time stock prices & the company’s financial overview to help with your trading & investment. Company Overview: autolus therapeutics - AUTL About autolus…
Autolus Therapeutics (AUTL) Receives a Buy from Wells Fargo
In a report released on October 2, from Wells Fargo maintained a Buy rating on Autolus Therapeutics, with a price target of $5.00. The company’... In a report released on October 2, from Wells Fargo maintained a Buy rating on Autolus…
H.C. Wainwright Keeps Their Buy Rating on Autolus Therapeutics (AUTL)
In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Autolus Therapeutics, with a price target of $10.00. According to TipRanks, Bodnar is a 4-star analyst with an average return of 4.1% and a 37.75%…
Autolus Therapeutics management to meet virtually with William Blair
Virtual Meeting to be held on September 24 hosted by William Blair. Published first on TheFly – the ultimate source for real-time, market-movin... Autolus Therapeutics management to meet virtually with William Blair Virtual Meeting to be…
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Abstract : 2216Title : Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- markets.businessinsider.com3
- seekingalpha.com2
- autolus.gcs-web.com1
- foxbusiness.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.